Deferasirox 400mg Tablets

Deferasirox 400mg Tablets is a highly effective oral iron-chelating agent designed to manage chronic iron overload in patients who require frequent blood transfusions. In conditions like Thalassemia or Myelodysplastic Syndromes, the body lacks a natural mechanism to excrete the excess iron gained from transfused red blood cells. This medication works as a tridentate chelator, meaning it has a high and specific affinity for trivalent (ferric) iron. Each molecule of Deferasirox binds to iron in a 2:1 ratio, forming a stable, non-toxic complex that is then excreted primarily through the feces via the bile. By removing this “free iron” from the blood and tissues, the drug prevents iron-mediated oxidative damage to vital organs such as the heart, liver, and endocrine glands. Discover how this professional pharmaceutical intervention provides the ultimate clinical strategy for long-term iron management, offering a convenient oral alternative to painful, multi-hour infusions of older chelators.

The 400mg tablet is a high-potency dosage unit designed to streamline the daily regimen for adult patients and those with significant iron burdens. For many patients, the required therapeutic dose is calculated by body weight (typically 14 mg/kg to 28 mg/kg for film-coated tablets), often necessitating total daily doses between 720mg and 1440mg. The 400mg strength significantly reduces the “pill burden,” allowing patients to achieve their target dose with fewer tablets compared to lower strengths. Modern film-coated formulations, like the 400mg tablet, offer superior gastrointestinal tolerability and more consistent absorption compared to older dispersible versions that required dissolution in liquid.

Indications and Uses of Deferasirox 400mg Tablets

Deferasirox 400mg Tablets is commonly prescribed for the specialized management of the following conditions:

• Transfusional Iron Overload: It is indicated for the treatment of chronic iron overload due to blood transfusions (hemosiderosis) in adult and pediatric patients (aged 2 years and older).
• Non-Transfusion-Dependent Thalassemia (NTDT): The medication is used for the treatment of chronic iron overload in patients with non-transfusion-dependent thalassemia syndromes aged 10 years and older who have a liver iron concentration (LIC) of at least 5 mg Fe/g dry weight.

Key Features of Deferasirox 400mg Tablets

• High Specificity for Iron: The primary feature of Deferasirox 400mg Tablets is its selective binding to ferric iron, sparing other essential minerals like zinc or copper.
• Reduced Pill Burden: The 400mg unit is optimized for adult dosing, making it easier for patients to adhere to high-dose daily requirements.
• Oral Convenience: It replaces the need for burdensome, 8-to-12-hour subcutaneous infusions, significantly enhancing patient quality of life.
• 24-Hour Coverage: Its long half-life allows for once-daily dosing, providing continuous chelation and protection against iron-induced organ damage.
• Film-Coated Technology: This formulation can be swallowed whole and does not require the complex preparation associated with older dispersible tablets.

Storage for Deferasirox 400mg Tablets

To preserve the pharmacological stability and ultimate potency of the active ingredients, Deferasirox 400mg Tablets should be stored at controlled room temperature, typically between 20°C and 25°C (68°F to 77°F). It is vital to keep the tablets in their original blister pack or bottle, protected from moisture and light. Do not remove the desiccant from the bottle if one is present. For maximum safety, always store Deferasirox 400mg Tablets in a secure, high location that is strictly out of the reach and sight of children and pets.

Safety Warnings for Deferasirox 400mg Tablets

The administration of Deferasirox 400mg Tablets is associated with serious Black Box Warnings regarding kidney and liver function. Nephrotoxicity (kidney damage) and Hepatic Failure have occurred, sometimes with fatal outcomes. Serum creatinine must be checked twice before starting therapy and monitored monthly thereafter. Liver function tests (ALT, AST, Bilirubin) must also be checked monthly.

Gastrointestinal Hemorrhage: Severe, sometimes fatal, stomach or intestinal bleeding has been reported, especially in elderly patients or those with low platelet counts. Cytopenias: It can cause severe decreases in blood counts (leukopenia, thrombocytopenia, anemia); regular blood monitoring is required.

Vision and Hearing: It may cause cataracts or hearing loss; baseline and annual eye and ear exams are recommended. Deferasirox 400mg Tablets can cause fetal harm (Pregnancy Category C/D); effective contraception is mandatory. By strictly following these professional guidelines and monitoring kidney and liver labs, healthcare providers can safely maximize the organ-protective benefits of Deferasirox 400mg Tablets.